FR21C1039I2 - COMPOUNDS FOR THE TREATMENT OF SPINAL TUSKIVE ATROPHY - Google Patents

COMPOUNDS FOR THE TREATMENT OF SPINAL TUSKIVE ATROPHY

Info

Publication number
FR21C1039I2
FR21C1039I2 FR21C1039C FR21C1039C FR21C1039I2 FR 21C1039 I2 FR21C1039 I2 FR 21C1039I2 FR 21C1039 C FR21C1039 C FR 21C1039C FR 21C1039 C FR21C1039 C FR 21C1039C FR 21C1039 I2 FR21C1039 I2 FR 21C1039I2
Authority
FR
France
Prior art keywords
tuskive
atrophy
spinal
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1039C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
PTC Therapeutics Inc
Original Assignee
F Hoffmann La Roche AG
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1039(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, PTC Therapeutics Inc filed Critical F Hoffmann La Roche AG
Publication of FR21C1039I1 publication Critical patent/FR21C1039I1/fr
Application granted granted Critical
Publication of FR21C1039I2 publication Critical patent/FR21C1039I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR21C1039C 2014-05-15 2021-09-09 COMPOUNDS FOR THE TREATMENT OF SPINAL TUSKIVE ATROPHY Active FR21C1039I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
PCT/EP2015/060343 WO2015173181A1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
FR21C1039I1 FR21C1039I1 (en) 2021-10-15
FR21C1039I2 true FR21C1039I2 (en) 2022-09-02

Family

ID=53175048

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1039C Active FR21C1039I2 (en) 2014-05-15 2021-09-09 COMPOUNDS FOR THE TREATMENT OF SPINAL TUSKIVE ATROPHY

Country Status (36)

Country Link
US (1) US9969754B2 (en)
EP (3) EP3143025B1 (en)
JP (1) JP6236173B2 (en)
KR (2) KR102213740B1 (en)
CN (1) CN106459092B (en)
AR (1) AR100442A1 (en)
AU (1) AU2015261046C1 (en)
BR (1) BR112016026205B1 (en)
CA (1) CA2948561C (en)
CL (1) CL2016002836A1 (en)
CR (1) CR20160518A (en)
DK (1) DK3143025T3 (en)
EA (2) EA035068B1 (en)
ES (2) ES2949660T3 (en)
FR (1) FR21C1039I2 (en)
HR (2) HRP20230637T1 (en)
HU (2) HUE046491T2 (en)
IL (2) IL248653B (en)
LT (1) LTPA2021010I1 (en)
MA (2) MA39995B1 (en)
MX (1) MX371050B (en)
MY (1) MY174284A (en)
NL (1) NL301128I2 (en)
NO (1) NO2021035I1 (en)
NZ (1) NZ725008A (en)
PE (1) PE20170128A1 (en)
PH (1) PH12016502081A1 (en)
PL (2) PL3143025T3 (en)
PT (1) PT3143025T (en)
RS (1) RS59718B1 (en)
SG (1) SG11201609497TA (en)
SI (2) SI3663296T1 (en)
TW (1) TWI667239B (en)
UA (1) UA119670C2 (en)
WO (1) WO2015173181A1 (en)
ZA (1) ZA201607026B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014019750B1 (en) 2012-02-10 2020-03-03 F. Hoffmann-La Roche Ag. COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USES
MX2016001963A (en) 2013-08-19 2016-05-26 Hoffmann La Roche Screening method.
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
CN107635999B (en) 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 Compounds for the treatment of spinal muscular atrophy
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CA3002494C (en) * 2015-11-12 2021-01-12 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
CN108137601A (en) * 2015-11-12 2018-06-08 豪夫迈·罗氏有限公司 For treating the compound of amyotrophic lateral sclerosis
CN108137579B (en) 2015-12-10 2022-01-07 豪夫迈·罗氏有限公司 Bridged piperidine derivatives
WO2017100726A1 (en) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
EP3544435A4 (en) 2016-11-28 2020-11-04 PTC Therapeutics, Inc. Methods for modulating rna splicing
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2018232039A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
WO2019005980A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
JP7075484B2 (en) * 2017-09-22 2022-05-25 エフ．ホフマン－ラ ロシュ アーゲー 7- (4,7-Diazaspiro [2.5] octane-7-yl) -2- (2,8-dimethylimidazole [1,2-b] pyridazine-6-yl) pyrido [1,2-a] Method for Producing Pyrimidine-4-one Derivative
AU2018344402A1 (en) * 2017-10-03 2020-04-09 F. Hoffmann-La Roche Ag New treatment of SMA
SG11202009212WA (en) 2018-03-27 2020-10-29 Ptc Therapeutics Inc Compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210042265A (en) 2018-06-27 2021-04-19 피티씨 테라퓨틱스, 인크. Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
CA3116458C (en) 2018-10-19 2023-12-12 F. Hoffmann-La Roche Ag New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
CN113966219A (en) 2019-06-12 2022-01-21 豪夫迈·罗氏有限公司 Novel treatment of SMA
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (en) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Crystal form of risdiplam, preparation method therefor, and use thereof
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
MX2023010719A (en) 2021-03-17 2023-09-20 Hoffmann La Roche New thiazolopyrimidinone derivatives.
CN116981673A (en) * 2021-03-17 2023-10-31 豪夫迈·罗氏有限公司 Novel thiadiazolopyrimidinone derivatives
CA3210678A1 (en) 2021-03-18 2022-09-22 F. Hoffmann-La Roche Ag Novel process
CN118055767A (en) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 Novel combined application
CN118005654A (en) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 Substituted pyridopyrimidinone compounds, compositions containing the same and uses thereof
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ292806B6 (en) * 1996-08-06 2003-12-17 Pfizer Inc. Pyrido- or pyrimido-6,6- or -6,7-bicyclic derivatives and pharmaceutical compositions based thereon
EP2573080A1 (en) 2007-09-27 2013-03-27 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (en) 2008-07-28 2010-02-08 신호열 A mouse for notebook-pc
US8986935B2 (en) 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US8126566B2 (en) * 2008-08-14 2012-02-28 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
EP2797592B1 (en) * 2011-12-30 2019-08-28 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
BR112014019750B1 (en) 2012-02-10 2020-03-03 F. Hoffmann-La Roche Ag. COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USES
WO2014012050A2 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
CA3002494C (en) 2015-11-12 2021-01-12 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
FR21C1039I1 (en) 2021-10-15
EA202090486A2 (en) 2020-06-30
HRP20192159T1 (en) 2020-02-21
HUE046491T2 (en) 2020-03-30
UA119670C2 (en) 2019-07-25
IL270027B (en) 2020-08-31
KR20210014219A (en) 2021-02-08
HRP20230637T1 (en) 2023-09-29
EA202090486A3 (en) 2020-08-31
PL3143025T3 (en) 2020-03-31
EP3663296B1 (en) 2023-05-17
DK3143025T3 (en) 2019-12-09
SI3663296T1 (en) 2023-08-31
BR112016026205A2 (en) 2017-08-15
KR102256013B1 (en) 2021-05-26
RS59718B1 (en) 2020-01-31
JP6236173B2 (en) 2017-11-22
EP4241772A3 (en) 2023-11-15
NL301128I2 (en) 2021-10-25
AU2015261046B2 (en) 2019-04-18
TWI667239B (en) 2019-08-01
KR102213740B1 (en) 2021-02-09
MY174284A (en) 2020-04-01
JP2017515863A (en) 2017-06-15
EA201692280A1 (en) 2018-07-31
EP3143025B1 (en) 2019-10-09
EA035068B1 (en) 2020-04-23
EP3663296A1 (en) 2020-06-10
AU2015261046C1 (en) 2019-07-25
NO2021035I1 (en) 2021-09-10
CL2016002836A1 (en) 2017-04-21
MA39995B1 (en) 2019-11-29
SG11201609497TA (en) 2016-12-29
NZ725008A (en) 2019-11-29
ES2761423T3 (en) 2020-05-19
US9969754B2 (en) 2018-05-15
EP4241772A2 (en) 2023-09-13
CN106459092B (en) 2019-10-15
WO2015173181A1 (en) 2015-11-19
US20170197990A1 (en) 2017-07-13
KR20170003687A (en) 2017-01-09
CA2948561A1 (en) 2015-11-19
PT3143025T (en) 2019-12-03
CR20160518A (en) 2017-02-21
ES2949660T3 (en) 2023-10-02
CN106459092A (en) 2017-02-22
HUS2100037I1 (en) 2021-10-28
MX2016014547A (en) 2017-02-23
NL301128I1 (en) 2021-09-22
MX371050B (en) 2020-01-14
ZA201607026B (en) 2022-05-25
LTPA2021010I1 (en) 2021-10-11
AR100442A1 (en) 2016-10-05
BR112016026205A8 (en) 2021-07-20
PE20170128A1 (en) 2017-03-16
CA2948561C (en) 2019-10-22
IL248653B (en) 2019-11-28
SI3143025T1 (en) 2020-01-31
IL248653A0 (en) 2017-01-31
EP3143025A1 (en) 2017-03-22
BR112016026205B1 (en) 2021-12-07
AU2015261046A1 (en) 2016-10-27
PL3663296T3 (en) 2023-08-07
PH12016502081A1 (en) 2017-01-09
MA51988A (en) 2021-01-20
TW201609738A (en) 2016-03-16

Similar Documents

Publication Publication Date Title
FR21C1039I2 (en) COMPOUNDS FOR THE TREATMENT OF SPINAL TUSKIVE ATROPHY
ZA201608108B (en) Huntington's disease therapeutic compounds
DK3386511T3 (en) PROCEDURES FOR THE TREATMENT OF HUNTINGTON'S DISEASE
EP3448874A4 (en) Compositions for the treatment of disease
EP3448875A4 (en) Compositions for the treatment of disease
EP3448987A4 (en) Compositions for the treatment of disease
DK3347030T3 (en) USE OF PASTEURIZED AKKERMANSIA FOR THE TREATMENT OF METABLE DISEASES
MA44702A (en) EXTENDED-RELEASE SUSPENSION COMPOSITIONS
DK3125875T3 (en) INHALABLE RAPAMYCINFORMULATION FOR THE TREATMENT OF AGING-RELATED CONDITIONS
IL265528A (en) Aav treatment of huntington's disease
DK3474804T4 (en) MEDICAL COMPOUND
DK3362066T3 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
DK3240612T3 (en) PROCEDURES FOR THE TREATMENT OF RHINTH DISEASES
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
HK1244482A1 (en) Combinations for the treatment of neuroblastoma
MA41169A (en) WIDE-SPECTRUM ANTIBACTERIAL COMPOUNDS
EP3316788A4 (en) Obstetrical imaging at the point of care for untrained or minimally trained operators
IL259297A (en) Heterocyclic compounds for the treatment of disease
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
DK3506901T3 (en) USE OF KYNURIC ACID FOR THE TREATMENT OF MUSCLE ATROPHY
DK3724173T3 (en) Compounds for the treatment of neuromuscular disorders
DK3302573T3 (en) COMPOSITION FOR THE TREATMENT OF BRAIN LESSIONS
DK3209295T3 (en) PROCEDURES FOR THE TREATMENT OF EYE DISORDERS
JP1671730S (en) Components for tubs for medical humidifiers
IT201600121617A1 (en) COMPOSITION FOR THE TREATMENT OF GASTROESOFAGEO REFLUX